JP2016520615A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520615A5 JP2016520615A5 JP2016517030A JP2016517030A JP2016520615A5 JP 2016520615 A5 JP2016520615 A5 JP 2016520615A5 JP 2016517030 A JP2016517030 A JP 2016517030A JP 2016517030 A JP2016517030 A JP 2016517030A JP 2016520615 A5 JP2016520615 A5 JP 2016520615A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- administration
- disease
- group
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361829713P | 2013-05-31 | 2013-05-31 | |
| US61/829,713 | 2013-05-31 | ||
| PCT/US2014/040160 WO2014194166A1 (en) | 2013-05-31 | 2014-05-30 | Methods of using il-1 antagonists to treat alzheimer's disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018076729A Division JP2018111723A (ja) | 2013-05-31 | 2018-04-12 | アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016520615A JP2016520615A (ja) | 2016-07-14 |
| JP2016520615A5 true JP2016520615A5 (enExample) | 2017-05-18 |
Family
ID=51023151
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016517030A Pending JP2016520615A (ja) | 2013-05-31 | 2014-05-30 | アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法 |
| JP2018076729A Pending JP2018111723A (ja) | 2013-05-31 | 2018-04-12 | アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018076729A Pending JP2018111723A (ja) | 2013-05-31 | 2018-04-12 | アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20160120941A1 (enExample) |
| EP (1) | EP3003356B1 (enExample) |
| JP (2) | JP2016520615A (enExample) |
| AU (1) | AU2014274044B2 (enExample) |
| CA (1) | CA2911547A1 (enExample) |
| WO (1) | WO2014194166A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016264228B2 (en) * | 2015-05-18 | 2019-06-13 | Synaptec Development Llc | Galantamine clearance of amyloidß |
| CA3036511A1 (en) * | 2016-09-12 | 2018-03-15 | Steven Hoffman | Compositions for treating dementia |
| JP7657440B2 (ja) | 2017-06-12 | 2025-04-07 | ブルーフィン バイオメディシン， インコーポレイテッド | 抗－ｉｌ１ｒａｐ抗体および抗体薬物コンジュゲート |
| JP7368856B2 (ja) | 2017-07-25 | 2023-10-25 | トゥルーバインディング，インコーポレイテッド | Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療 |
| JP7290872B2 (ja) * | 2018-01-31 | 2023-06-14 | オラテック セラピューティクス リミティド ライアビリティ カンパニー | アルツハイマー病の予防又は治療方法 |
| CN120058944A (zh) | 2019-01-30 | 2025-05-30 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| JP2023528797A (ja) | 2020-05-26 | 2023-07-06 | トゥルーバインディング，インコーポレイテッド | ガレクチン－３を遮断することにより炎症性疾患を処置する方法 |
| CN111956933B (zh) * | 2020-08-27 | 2022-05-03 | 北京理工大学 | 一种阿尔兹海默病神经反馈康复系统 |
| WO2022167916A1 (en) * | 2021-02-03 | 2022-08-11 | Novartis Ag | Use of il-1b binding antibodies for treating neuroinflammatory disorders |
| EP4464329A4 (en) * | 2022-01-10 | 2025-06-11 | GI Innovation, Inc. | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DEGENERATIVE BRAIN DISEASES, CONTAINING A GLUCAGON-LIKE PEPTIDE-1 AND AN INTERLEUKIN-1 RECEPTOR ANTAGONIST |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965421A (en) * | 1997-11-26 | 1999-10-12 | Human Genome Sciences, Inc. | Human IRAK-2 |
| US6927044B2 (en) * | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US8119127B2 (en) * | 1999-02-24 | 2012-02-21 | Tact Ip, Llc | Cytokine antagonists for neurological and neuropsychiatric disorders |
| US7629311B2 (en) * | 1999-02-24 | 2009-12-08 | Edward Lewis Tobinick | Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers |
| US6623736B2 (en) * | 2000-05-02 | 2003-09-23 | Edward L. Tobinick | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders |
| CN100424182C (zh) * | 2001-06-15 | 2008-10-08 | 白介素遗传公司 | 衰老相关疾病早期发作的检测与治疗方法 |
| US7217807B2 (en) * | 2002-11-26 | 2007-05-15 | Rosetta Genomics Ltd | Bioinformatically detectable group of novel HIV regulatory genes and uses thereof |
| US20050129685A1 (en) * | 2003-09-18 | 2005-06-16 | Jingtai Cao | Use of IL-1 blockers to prevent corneal inflammation and neovascularization |
| US8618054B2 (en) * | 2004-05-05 | 2013-12-31 | Valorisation-Rechereche Société en Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| MXPA06014126A (es) * | 2004-06-04 | 2007-07-18 | Regeneron Pharma | Metodos para utilizar antagonistas il-1 para tratar enfermedades auto-inflamatorias. |
| JP2008523815A (ja) * | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミテッド | 認知の改善における使用のためのヒト化アミロイドβ抗体 |
| EP2163562B1 (en) * | 2005-06-21 | 2013-09-18 | XOMA Technology Ltd. | IL-1beta binding antibodies and fragments thereof |
| US20070065415A1 (en) * | 2005-09-16 | 2007-03-22 | Kleinsek Donald A | Compositions and methods for the augmentation and repair of defects in tissue |
| RU2011105466A (ru) * | 2008-08-28 | 2012-10-10 | ВАЙЕТ ЭлЭлСи (US) | Применения цитокинов семейств il-22, il-17 и il-1 при аутоиммунных заболеваниях |
| ES2713873T3 (es) * | 2010-04-16 | 2019-05-24 | Nuevolution As | Complejos bifuncionales y métodos para hacer y utilizar tales complejos |
| CN107337735B (zh) * | 2010-07-29 | 2021-06-22 | 巴扎德制药公司 | 嵌合il-1受体i型激动剂和拮抗剂 |
| ES2600616T3 (es) * | 2011-03-14 | 2017-02-10 | Phlogo Aps | Antagonistas del receptor de la interleucina-1 |
-
2014
- 2014-05-30 JP JP2016517030A patent/JP2016520615A/ja active Pending
- 2014-05-30 AU AU2014274044A patent/AU2014274044B2/en not_active Ceased
- 2014-05-30 CA CA2911547A patent/CA2911547A1/en not_active Abandoned
- 2014-05-30 EP EP14733888.3A patent/EP3003356B1/en active Active
- 2014-05-30 US US14/893,932 patent/US20160120941A1/en not_active Abandoned
- 2014-05-30 WO PCT/US2014/040160 patent/WO2014194166A1/en not_active Ceased
-
2018
- 2018-04-12 JP JP2018076729A patent/JP2018111723A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016520615A5 (enExample) | ||
| Cao et al. | Postoperative cognitive deficits and neuroinflammation in the hippocampus triggered by surgical trauma are exacerbated in aged rats | |
| Okuma et al. | Glycyrrhizin inhibits traumatic brain injury by reducing HMGB1–RAGE interaction | |
| Ryu et al. | Pharmacological antagonism of interleukin-8 receptor CXCR2 inhibits inflammatory reactivity and is neuroprotective in an animal model of Alzheimer’s disease | |
| JP2011507891A5 (enExample) | ||
| JP2017158561A5 (enExample) | ||
| JP2017042172A5 (enExample) | ||
| HRP20210559T1 (hr) | Pripravci i postupci inhibiranja masp-1 i/ili masp-2 i/ili masp-3 za liječenje raznih bolesti i poremećaja | |
| Ma et al. | Ribonuclease attenuates hepatic ischemia reperfusion induced cognitive impairment through the inhibition of inflammatory cytokines in aged mice | |
| AU2016215035A1 (en) | Compounds and uses in treatment of senescence-associated conditions | |
| Ahmed et al. | Angiotensin receptor (AT2R) agonist C21 prevents cognitive decline after permanent stroke in aged animals—A randomized double-blind pre-clinical study | |
| JP2018511327A5 (enExample) | ||
| JP2016506391A5 (enExample) | ||
| Goel et al. | Hypertension exacerbates predisposition to neurodegeneration and memory impairment in the presence of a neuroinflammatory stimulus: protection by angiotensin converting enzyme inhibition | |
| EA201490277A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| JP2019507781A5 (enExample) | ||
| JP2013533287A5 (enExample) | ||
| JP2019519533A5 (enExample) | ||
| JP2019518779A5 (enExample) | ||
| WO2017072335A1 (en) | Use of masitinib and other mast cell inhibitors for treatment of parkinson's disease | |
| JP2018516944A5 (enExample) | ||
| JP2018529661A5 (enExample) | ||
| JP2018534259A5 (enExample) | ||
| JP2014529606A5 (enExample) | ||
| JP2011500776A5 (enExample) |